Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News

Zacks2021-09-13

A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

PorkChopRice
2021-09-13
PorkChopRice
$Moderna, Inc.(MRNA)$ has risen too much and maybe ETFs are the way to invest in it and other biotech companies but be careful of buying ETFs since the expense ratio is high (35 to 68 basis points). Maybe put some cash into Moderna directly, or buy options? [疑問] [疑問] [疑問]
Jahme
2021-09-13
Jahme
Too high ?
- Jahme:
  [Sweats]
YunaTuna
2021-09-13
YunaTuna
O
Swifty
2021-09-13
Swifty
??
DKim
2021-09-13
DKim
That’s gd
AlphaOmega
2021-09-13
AlphaOmega
It will lure better upside if the Booster Shot is effective enough.
- YunaTuna:
  ok

Leave a comment

172

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2167052753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-13 07:36","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2167052753","market":"us","top_or_hot":-1,"title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","media":"Zacks","content":"<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","article_id":"2167052753","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","pubTimestamp":1631489769,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","NWS":"新闻集团"},"translate_title":"莫德纳ETF将在二合一疫苗强化注射新闻上反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"NWS":0.9},"content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":888660230,"gmtCreate":1631493854720,"gmtModify":1676530555989,"author":{"id":"3555134782523638","authorId":"3555134782523638","name":"PorkChopRice","avatar":"https://static.tigerbbs.com/a98cc137c6872d5c9d28edd7d7e4206a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3555134782523638","authorIdStr":"3555134782523638"},"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> has risen too much and maybe ETFs are the way to invest in it and other biotech companies but be careful of buying ETFs since the expense ratio is high (35 to 68 basis points). Maybe put some cash into Moderna directly, or buy options?&nbsp;[疑問]&nbsp;[疑問]&nbsp;[疑問]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> has risen too much and maybe ETFs are the way to invest in it and other biotech companies but be careful of buying ETFs since the expense ratio is high (35 to 68 basis points). Maybe put some cash into Moderna directly, or buy options?&nbsp;[疑問]&nbsp;[疑問]&nbsp;[疑問]&nbsp;","text":"$Moderna, Inc.(MRNA)$ has risen too much and maybe ETFs are the way to invest in it and other biotech companies but be careful of buying ETFs since the expense ratio is high (35 to 68 basis points). Maybe put some cash into Moderna directly, or buy options? [疑問] [疑問] [疑問]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888660230","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":888681716,"gmtCreate":1631493459435,"gmtModify":1676530555821,"author":{"id":"3577502940596690","authorId":"3577502940596690","name":"Jahme","avatar":"https://static.tigerbbs.com/d07b4bec5131f225dae7aadbfebc0c02","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577502940596690","authorIdStr":"3577502940596690"},"htmlText":"Too high ?&nbsp;","listText":"Too high ?&nbsp;","text":"Too high ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888681716","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5846598,"gmtCreate":1631493483523,"gmtModify":1631889264923,"authorId":3577502940596690,"author":{"id":3577502940596690,"idStr":"3577502940596690","authorId":3577502940596690,"name":"Jahme","avatar":"https://static.tigerbbs.com/d07b4bec5131f225dae7aadbfebc0c02","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":888681716,"type":1,"supId":0,"prevId":0,"content":"[Sweats]","text":"[Sweats]","html":"[Sweats]"}],"langContent":"EN"},{"id":888683791,"gmtCreate":1631493401213,"gmtModify":1676530555790,"author":{"id":"3581809523229784","authorId":"3581809523229784","name":"YunaTuna","avatar":"https://static.tigerbbs.com/6463ed1450c2454bfc57b76274b06418","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581809523229784","authorIdStr":"3581809523229784"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888683791","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":888633644,"gmtCreate":1631492352088,"gmtModify":1676530555290,"author":{"id":"3573686260747225","authorId":"3573686260747225","name":"Swifty","avatar":"https://static.tigerbbs.com/25bc2f32857ae0c620f1d9eee6447454","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573686260747225","authorIdStr":"3573686260747225"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888633644","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":888697282,"gmtCreate":1631492224846,"gmtModify":1676530555221,"author":{"id":"3572428109068921","authorId":"3572428109068921","name":"DKim","avatar":"https://static.tigerbbs.com/2bcfaaf6da9577d8a6da421538592a0e","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":7,"crmLevelSwitch":1,"idStr":"3572428109068921","authorIdStr":"3572428109068921"},"htmlText":"That’s gd","listText":"That’s gd","text":"That’s gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888697282","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":888606236,"gmtCreate":1631491516925,"gmtModify":1676530554848,"author":{"id":"4094019191031610","authorId":"4094019191031610","name":"AlphaOmega","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094019191031610","authorIdStr":"4094019191031610"},"htmlText":"It will lure better upside&nbsp;if the Booster Shot is effective enough.&nbsp;","listText":"It will lure better upside&nbsp;if the Booster Shot is effective enough.&nbsp;","text":"It will lure better upside if the Booster Shot is effective enough.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888606236","repostId":2167052753,"repostType":4,"repost":{"id":"2167052753","kind":"news","pubTimestamp":1631489769,"share":"https://ttm.financial/m/news/2167052753?lang=&edition=fundamental","pubTime":"2021-09-13 07:36","market":"us","language":"en","title":"Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News","url":"https://stock-news.laohu8.com/highlight/detail?id=2167052753","media":"Zacks","summary":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a ra","content":"<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-<a href=\"https://laohu8.com/S/AONE.U\">one</a> vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.</p>\n<p>Moderna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization&nbsp;(WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the&nbsp;European Union&nbsp;and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).</p>\n<p>Notably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.</p>\n<h3>Moderna ETFs to Gain</h3>\n<p>Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.</p>\n<p>Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.</p>\n<p>Therefore, we discuss a few ETFs that provide exposure to Moderna<b>:</b></p>\n<p><b><a href=\"https://laohu8.com/S/GERM\">ETFMG Treatments Testing and Advancements ETF</a>&nbsp;</b>GERM</p>\n<p>This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read:&nbsp;Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).</p>\n<p><b>VanEck Biotech ETF&nbsp;</b>BBH</p>\n<p>The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read:&nbsp;Best ETF Areas for Placing Your Bets in September).</p>\n<p><b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Biotechnology ETF&nbsp;</b>IBB</p>\n<p>This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read:&nbsp;Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).</p>\n<p><b><a href=\"https://laohu8.com/S/EGRW\">iShares</a> Genomics Immunology and Healthcare ETF&nbsp;</b>IDNA</p>\n<p>The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna ETFs to Rally on Two-in-One Vaccine Booster Shot News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-etfs-rally-two-one-215809649.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167052753","content_text":"A formidable name among the COVID-19 vaccine developers, Moderna MRNA, impressed investors with a rally of 7.8% on Sep 9. The shares of the biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines soared as it informed about developing a two-in-one vaccine booster shot that will provide shield against both COVID-19 and the seasonal flu. Moderna plans to name the new vaccine mRNA-1073, which will be a combination of the company’s present coronavirus vaccine along with a flu shot that is presently under development.\nModerna’s COVID-19 vaccine for adults has already received the emergency use authorization or emergency use listing from the World Health Organization (WHO) and health authorities in more than 50 countries. The company has also been granted approval for the application of its COVID-19 vaccine in adolescents aged 12 years and above in the European Union and other jurisdictions. Moderna duly completed the submission process for a Biologics License Application (BLA) for the vaccine in the United States on Aug 25. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million of the Moderna shots have been provided in the United States (per a CNBC article).\nNotably, Moderna recently informed about new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of the people who received both the shots of Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.\nModerna ETFs to Gain\nConsidering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be a positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.\nInterestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine drove revenues.\nTherefore, we discuss a few ETFs that provide exposure to Moderna:\nETFMG Treatments Testing and Advancements ETF GERM\nThis fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 12.15% share. The fund has amassed $70.1 million in its asset base and charges 68 basis points (bps) in annual fees (read: Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases).\nVanEck Biotech ETF BBH\nThe underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 11.17% exposure to Moderna. Its AUM is $630.9 million and it has an expense ratio of 0.35% (read: Best ETF Areas for Placing Your Bets in September).\niShares Biotechnology ETF IBB\nThis fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 269 securities in its basket, with 11.14% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs).\niShares Genomics Immunology and Healthcare ETF IDNA\nThe fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 7.79% exposure to Moderna. IDNA has AUM of $370 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5846567,"gmtCreate":1631493392173,"gmtModify":1663233789049,"authorId":3581809523229784,"author":{"id":3581809523229784,"idStr":"3581809523229784","authorId":3581809523229784,"name":"YunaTuna","avatar":"https://static.tigerbbs.com/6463ed1450c2454bfc57b76274b06418","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":888606236,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":172,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2167052753"}